A mucosal vaccine coulld someday serve as a booster to help prevent infection and transmission of SARS-CoV-2.

Thursday, April 13, 2023 The Potential and Challenges of Mucosal COVID-19 Vaccines Although currently vaccines for COVID-19 are usually effective, researchers are still investigating how future vaccines could be improved. A mucosal vaccine, which could improve the immune response in recipients' respiratory tracts, could someday serve as a booster to help prevent infection and transmission of the SARS-CoV-2 virus. In a virtual workshop in 2022, supported in part by NIAID, participants discussed the potential of mucosal vaccines currently in development, and some of the challenges which researchers have faced. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107